Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

详细信息    查看全文

• 作者：Aida Kiviniemi ; Maria Gardberg ; Janek Frantzén…
• 关键词：High ; grade glioma ; Serum biomarker ; GFAP ; EGFR ; Tumor volume ; Prognosis
• 刊名：Journal of Neuro-Oncology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：124
• 期：2
• 页码：237-245
• 全文大小：636 KB
• 参考文献：1.Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323-42CrossRef PubMed
  2.Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-92CrossRef PubMed
  3.Hygino da Cruz LC, Jr Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978-985CrossRef PubMed
  4.Holdhoff M, Yovino SG, Boadu O, Grossman SA (2013) Blood-based biomarkers for malignant gliomas. J Neurooncol 113:345-52PubMed Central CrossRef PubMed
  5.Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-000). Neurochem Res 25:1439-451CrossRef PubMed
  6.Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ (2000) Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31:2670-677CrossRef PubMed
  7.Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786-793CrossRef PubMed
  8.Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336-341CrossRef PubMed
  9.Husain H, Savage W, Grossman SA et al (2012) Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol 109:123-27PubMed Central CrossRef PubMed
  10.Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380-84CrossRef PubMed
  11.Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-453PubMed Central CrossRef PubMed
  12.Hegi ME, Rajakannu P, Weller M (2012) Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 25:774-79CrossRef PubMed
  13.Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962-970PubMed
  14.Oh MJ, Choi JH, Kim IH et al (2000) Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 6:4760-763PubMed
  15.Lafky JM, Wilken JA, Baron AT, Maihle NJ (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232-65PubMed
  16.Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N (2010) Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 70:43-0CrossRef PubMed
  17.Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL, Robertson JF (2007) Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 9:R75PubMed Central CrossRef PubMed
  18.Quaranta M, Divella R, Daniele A, Di Tardo S, Venneri MT, Lolli I, Troccoli G (2007) Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 93:275-80PubMed
  19.Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599-01CrossRef PubMed
  20.?lgars A, Lintunen M, Carpen O, Ristam?ki R, Sundstr?m J (2011) EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br J Cancer 105:255-62PubMed Central CrossRef PubMed
  21.Tuononen K, Tynninen O, Sarhadi VK et al (2012) The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas—correlation with array comparative genome hybridization results and IDH1 mutation. Genes Chromosomes Cancer 51:20-9CrossRef PubMed
  22.Ilhan-Mutlu A, Wagner L, Widhalm G et al (2013) Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev 36:45-6CrossRef PubMed
  23.Horbinski C (2013) What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 125:621-36PubMed Central CrossRef PubMed
  24.Choi JH, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim YS, Yi SY, Shim KS, Han WS (1997) Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79:1879-883CrossRef PubMed
  
• 作者单位：Aida Kiviniemi (1)
  Maria Gardberg (2)
  Janek Frantzén (3)
  Riitta Parkkola (1)
  Ville Vuorinen (3)
  Marko Pesola (1)
  Heikki Minn (4)
  
  1. Department of Radiology, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521, Turku, Finland
  2. Department of Pathology, Turku University Hospital, University of Turku, Kiinamyllynkatu 4-8, 20521, Turku, Finland
  3. Department of Neurosurgery, Turku University Hospital, H?meentie 11, 20521, Turku, Finland
  4. Department of Oncology and Radiotherapy, Turku University Hospital, H?meentie 11, 20521, Turku, Finland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7373

文摘

Our aim was to study the association of two potential serum biomarkers glial fibrillary acidic protein (GFAP) and epidermal growth factor receptor (EGFR) with prognostic markers such as IDH1 mutation, tumor burden, and survival in patients with high-grade gliomas (HGG). Additionally, our objective was to evaluate the potential of serum EGFR as a surrogate marker for EGFR status in the tumor. Pre-operative serum samples were prospectively collected from patients with primary (n = 17) or recurrent (n = 10) HGG. Serum GFAP and EGFR levels were determined by ELISA and studied for correlation with molecular markers including EGFR amplification, tumor volume in contrast-enhanced T1-weighted MRI, and progression-free survival (PFS). Pre-operative serum GFAP level of ?.014 ng/ml was 86 % sensitive and 85 % specific for the diagnosis of glioblastoma. High GFAP was related to the lack of IDH1 mutation (P = 0.016), high Ki67 proliferation index (P < 0.001), and poor PFS (HR 5.9, CI 1.2-9.9, P = 0.032). Serum GFAP correlated with enhancing tumor volume in primary (r = 0.64 P = 0.005), but also in recurrent HGGs (r = 0.76 P = 0.011). In contrast, serum EGFR levels did not differ between HGG patients and 13 healthy controls, and were not related to EGFR status in the tumor. We conclude that high serum GFAP associates with IDH1 mutation-negative HGG, and poor PFS. Correlation with tumor burden in recurrent HGG implicates the potential of serum GFAP for detection of tumor recurrence. Our results suggest that circulating EGFR is not derived from glioma cells and cannot be used as a marker for EGFR status in the tumor. Keywords High-grade glioma Serum biomarker GFAP EGFR Tumor volume Prognosis